1. Home
  2. CRL vs DVA Comparison

CRL vs DVA Comparison

Compare CRL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Charles River Laboratories International Inc.

CRL

Charles River Laboratories International Inc.

HOLD

Current Price

$195.57

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$115.91

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRL
DVA
Founded
1947
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Misc Health and Biotechnology Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.4B
IPO Year
2000
1995

Fundamental Metrics

Financial Performance
Metric
CRL
DVA
Price
$195.57
$115.91
Analyst Decision
Buy
Hold
Analyst Count
14
4
Target Price
$191.00
$145.00
AVG Volume (30 Days)
794.4K
979.6K
Earning Date
11-05-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.63
EPS
N/A
9.76
Revenue
$4,023,704,000.00
$13,317,965,000.00
Revenue This Year
N/A
$6.50
Revenue Next Year
$1.66
$2.97
P/E Ratio
N/A
$12.13
Revenue Growth
N/A
5.14
52 Week Low
$91.86
$113.97
52 Week High
$200.58
$179.60

Technical Indicators

Market Signals
Indicator
CRL
DVA
Relative Strength Index (RSI) 65.20 39.90
Support Level $194.50 $115.91
Resistance Level $200.58 $122.40
Average True Range (ATR) 5.45 2.58
MACD 1.24 0.13
Stochastic Oscillator 79.95 10.01

Price Performance

Historical Comparison
CRL
DVA

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Share on Social Networks: